Pharma sales are about to turn around big time. Negative effects of Concerta and Levaquin going generic will soon be eliminated. New products have a tremendous upside. Zytiga, Xarelto, Prezista added to strong growth in Remicade, Simponi and Stelara should ramp up sales significantly in the next 12 months.
When the manufacturing issues are resolved at McNeil, I am sure we will see an all out press of consumer advertising and promotion to regain business that has been lost in Tylenol and Motrin IB sales.
The integration of Synthes will also improve sales. JNJ has most of the rough water behind it and should be a good long term investment going forward.